Session Chair Profile
Ph.D., CSO, CEO & Chairman, Invivoscribe, Inc.
Biography
Jeffrey Miller, Ph.D. has two decades of experience with personalized molecular medicine®. He founded Invivoscribe® in 1995 without outside investment. The company is a highly profitable vertically integrated international network of six wholly-owned ISO13485 manufacturing and ISO15189 clinical testing companies. They are located in the U.S., Europe and Asia and operate under a single quality and regulatory system. The companies offer GMP test reagents, internationally harmonized clinical testing, and CRO services for stratification of patients for treatment and enrollment in clinical trials. Dr. Miller received his undergraduate degree in biochemistry from UCLA, and a combined Ph.D. in biochemistry & molecular biology from UCSB.
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: The nascent field of Precision Medicine depends on molecular testing to help physicians identify the right treatment for the right patient at the right time. Since clinical test results help define treatment, it follows that a bad test can be every bit as dangerous as a bad drug. Further, regulatory agencies, including the FDA, have expressed an interest and willingness to help pharmaceutical companies accelerate drug approval if molecular tests clearly demonstrate clinical efficacy. As virtually all drug trials depend on the stratification and enrollment of patients drawn from multiple clinical sites, often located around the world, accelerating drug trials depends both on more careful and uniform selection and better monitoring of patients.
This session is designed to provide evidence of the ongoing value of international harmonization and standardization of tests and bioinformatics for patient testing.
